United StatesThis article discusses how pharmaceutical companies like Merck & Co. (MSD outside the U.S.) exploit the global patent system to maintain extended market exclusivity for drugs such as Keytruda, a blockbuster cancer treatment. By filing numerous patent applications for minor modifications—such as dosage adjustments, combination therapies, or 'product hops'—companies create a complex web of patents that delays the entry of cheaper biosimilar alternatives into the market. This strategy keeps drug prices artificially high, strains healthcare systems, and limits patient access. The International Consortium of Investigative Journalists (ICIJ) analyzed these practices as part of its Cancer Calculus project, revealing how patent thickets contribute to prolonged monopolies. Additionally, the article highlights the variability of Keytruda's pricing across different countries and notes the growing trend of patients seeking legal recourse to access the drug due to its high cost.
Bias read (Center): The article presents a balanced investigation into the pharmaceutical industry's use of the patent system, highlighting both the mechanisms employed by companies and the resulting impact on patients and healthcare systems. It does not exhibit overtly biased language, one-sided sourcing, or editorial
